A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer

被引：1
|
作者：
Chigusa Morizane
Makoto Ueno
Masafumi Ikeda
Kentaro Sudo
Yoshinori Hirashima
Masataka Kuroda
Shinji Ueno
Takuji Okusaka
Junji Furuse
机构：
[1] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Oncology
[2] Hepatobiliary and Pancreatic Medical Oncology Division,Department of Gastroenterology
[3] Kanagawa Cancer Center,Department of Hepatobiliary and Pancreatic Oncology
[4] National Cancer Center Hospital East,Department of Gastroenterology
[5] Chiba Cancer Center,Clinical Development Headquarters
[6] Ono Pharmaceutical Co.,Department of Medical Oncology
[7] Ltd.,undefined
[8] Kyorin University Faculty of Medicine,undefined
[9] Kanagawa Cancer Center,undefined
来源：
BJC Reports | / 2卷 / 1期
关键词：
D O I：
10.1038/s44276-023-00028-4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer
    Ueno, Makoto
    Morizane, Chigusa
    Ikeda, Masafumi
    Sudo, Kentaro
    Hirashima, Yoshinori
    Kuroda, Masataka
    Fukuyama, Yuki
    Okusaka, Takuji
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer.
    Le, Dung T.
    Cruz-Correa, Marcia
    Bajor, David L.
    Garcia-Carbonero, Rocio
    Harris, Marion
    Pazo-Cid, Roberto
    Kindler, Hedy
    Yee, Nelson
    Kamath, Suneel
    Patel, Maulik
    Fang, Hua
    Henner, William
    Hardesty, Patrick
    Blaney, Martha
    McDevitt, Michael
    Golan, Talia
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
    Stacey M Stein
    Edward S James
    Yanhong Deng
    Xiangyu Cong
    Jeremy S Kortmansky
    Jia Li
    Carol Staugaard
    Doddamane Indukala
    Ann Marie Boustani
    Vatsal Patel
    Charles H Cha
    Ronald R Salem
    Bryan Chang
    Howard S Hochster
    Jill Lacy
    British Journal of Cancer, 2016, 114 : 737 - 743
  • [4] Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
    Stein, Stacey M.
    James, Edward S.
    Deng, Yanhong
    Cong, Xiangyu
    Kortmansky, Jeremy S.
    Li, Jia
    Staugaard, Carol
    Indukala, Doddamane
    Boustani, Ann Marie
    Patel, Vatsal
    Cha, Charles H.
    Salem, Ronald R.
    Chang, Bryan
    Hochster, Howard S.
    Lacy, Jill
    BRITISH JOURNAL OF CANCER, 2016, 114 (07) : 737 - 743
  • [5] Phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer
    Ueno, Makoto
    Ozaka, Masato
    Ishii, Hiroshi
    Sato, Tosiya
    Ikeda, Masafumi
    Uesugi, Kazuhiro
    Sata, Naohiro
    Miyashita, Kouichirou
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Okusaka, Takuji
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein, Stacey
    James, Edward Samuel
    Cong, Xiangyu
    Deng, Yanhong
    Salem, Ronald R.
    Cha, Charles
    Chang, Bryan William
    Hochster, Howard S.
    Doddamane, Indukala
    Boustani, Annmarie
    Patel, Vatsal
    Kortmansky, Jeremy S.
    Li, Jia
    Staugaard, Carol
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
    Masato Ozaka
    Hiroshi Ishii
    Tosiya Sato
    Makoto Ueno
    Masafumi Ikeda
    Kazuhiro Uesugi
    Naohiro Sata
    Kouichirou Miyashita
    Nobumasa Mizuno
    Kunihiro Tsuji
    Takuji Okusaka
    Junji Furuse
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 1017 - 1023
  • [8] A phase II study of modified FOLFIRINOX for chemotherapy-na⟨ve patients with metastatic pancreatic cancer
    Ozaka, Masato
    Ishii, Hiroshi
    Sato, Tosiya
    Ueno, Makoto
    Ikeda, Masafumi
    Uesugi, Kazuhiro
    Sata, Naohiro
    Miyashita, Kouichirou
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Okusaka, Takuji
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1017 - 1023
  • [9] Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population
    Li, Xiang
    Ma, Tao
    Zhang, Qi
    Chen, Yi-Gang
    Guo, Cheng-Xiang
    Shen, Yi-Nan
    Sun, Pei-Wei
    Li, Guo-Gang
    Gao, Shun-Liang
    Que, Ri-Sheng
    Lou, Jian-Ying
    Yu, Ri-Sheng
    Yuan, Ying
    Wei, Qi-Chun
    Wei, Shu-Mei
    Zhang, Yun
    Zheng, Lei
    Bai, Xue-Li
    Liang, Ting-Bo
    CANCER LETTERS, 2017, 406 : 22 - 26
  • [10] A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma
    Yin, Chao
    Marshall, John
    Macke, Laura Ann
    He, Aiwu Ruth
    Bouker, Kerrie
    Weinberg, Benjamin Adam
    Mukherji, Reetu
    Weiner, Louis M.
    Wang, Hongkun
    Geng, Xue
    Hoke, Frank
    Youssoufian, Hagop
    El-Hariry, Iman
    Noel, Marcus Smith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345